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ABSTRACT Testicular germ cell tumors are the most
common form ofcancer in young adult males. They result from
a derangement of primordial germ cells, and they grow out
from a noninvasive carcinoma-in-situ precursor. Since carci-
noma in situ can readily be cured by low-dose irradiation, there
is a great incentive for non- or minimally invasive methods for
detection of carcinoma in situ. We have recently shown that
human Tera-2 embryonal carcinoma cells, obtained from a
nonseminomatous testicular germ cell tumor, show alterna-
tive splicing and alternative promoter use of the platelet-
derived growth factor a-receptor gene, giving rise to a unique
1.5-kb transcript. In this study we have set up a reverse
transcriptase-polymerase chain reaction strategy for charac-
terization of the various transcripts for this receptor. Using
this technique, we show that a panel of 18 seminomas and 11
nonseminomatous testicular germ cell tumors all express the
1.5-kb transcript. In addition, a panel of 27 samples of testis
parenchyma with established carcinoma in situ were all found
to be positive for the 1.5-kb transcript, while parenchyma
lacking carcinoma in situ, placenta, and control semen were all
negative. These data show that the 1.5-kb platelet-derived
growth factor a-receptor transcript can be used as a highly
selective marker for detection of early stages of human tes-
ticular germ cell tumors.
Testicular germ cell tumors (TGCTs) of adolescents and adults
form the most common cancer in men between 20 and 45 years
of age (1, 2). They can be subdivided into seminomas (SEs),
composed of the neoplastic counterparts of primordial germ
cells, and nonseminomatous TGCTs (NSs). NS can contain a
variety of cell types in various states of differentiation and may
include mature and immature teratoma (TE), yolk sac tumor(YS), and choriocarcinoma (CH), in addition to a population
of undifferentiated stem cells, known as embryonal carcinoma(EC) cells (3). Various cell lines of human NS have been
established, including the Tera-2 EC line, which can be in-
duced to differentiate in vitro into a variety of nontumorigenic
mature cell types upon treatment with retinoic acid (RA) (4).
Carcinoma in situ (CIS) is the precursor of all TGCTs, and
it is believed to originate from a derangement of primordial
germ cells in early life (5, 6). The total incidence of CIS in the
Caucasian male population is 0.6%, and epidemiological evi-
dence suggests that CIS, once established, will sooner or later
always progress into an invasive TGCT (7). The overall cure
rate of TGCTs is relatively high, but cure requires orchidec-
tomy, mostly in combination with cisplatin treatment and/or
irradiation, and still some 20% of the patients die of their
disease. In contrast, CIS can readily be cured by low-dose
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irradiation (8), and therefore early detection could result in
significant reduction of the number of patients requiring
extensive treatment and an improved overall cure rate. Pres-
ently, CIS can be identified only morphologically and/or(immuno-)histochemically after'surgical biopsy. CIS-specific
markers would provide a major contribution to early detection
of this disease by allowing analysis of samples obtained by non-
or minimally invasive methods, including collection of semen
and cytological aspirates (9).
The platelet-derived growth factor (PDGF) a-receptor be-
longs to the tyrosine kinase family of growth factor receptors,
and it binds all isoforms ofPDGF (10). The PDGF a-receptor
gene is located on human chromosome 4 and is structurally
related to the PDGF 3-receptor gene and the c-kit and c-fms
protooncogenes (11). The PDGF a-receptor is expressed
during early mouse embryogenesis and upon further differen-
tiation in mesodermal and glial cells (11, 12). Mice with the
so-called Patch mutation lack the PDGF a-receptor gene,
resulting in recessive embryonic lethality characterized by
neuronal and mesodermal disorders (12). Cells expressing the
PDGF a-receptor show a characteristic 6.4-kb transcript,
which contains all information for the full-length receptor. We
have recently shown (13) that Tera-2 EC cells show expression
of the PDGF a-receptor gene with two aberrant transcripts of
5.0 kb and 1.5 kb instead. cDNA cloning combined with
genomic analysis showed that the 1.5-kb transcript results from
a combination of alternative promoter use and alternative
splicing of the PDGF a-receptor gene. Upon cellular differ-
entiation induced by RA, the 5.0-kb and 1.5-kb transcripts
disappeared and cells expressed the normal 6.4-kb transcript
instead (13).
In the present study we have set up a polymerase chain
reaction (PCR)-based strategy to detect the various PDGF
a-receptor transcripts in Tera-2 cells. First, we have found
evidence for an additional 3.0-kb transcript in differentiated
Tera-2 cells, potentially encoding a dominant-negative recep-
tor variant. Second, we have shown that the 1.5-kb transcript
is expressed not only in Tera-2 EC cells but also in a panel of
SE-, NS-, and CIS-containing parenchyma samples, while no
expression is observed in placenta, testis parenchyma without
CIS, and normal semen. The observed selectivity, in combi-
nation with the high sensitivity of the PCR assay, makes the
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1.5-kb PDGF a-receptor transcript an ideal marker for early
diagnosis of CIS.
MATERIALS AND METHODS
Cell Cultures. Tera-2 clone 13 cells were cultured and were
induced to differentiate by treatment with 5 ,LM RA as
described (13). Polyadenylated RNA was isolated from both
differentiated and undifferentiated Tera-2 cells by using oli-
godeoxythymidylate-cellulose affinity chromatography, sub-jected to 1% agarose gel electrophoresis in formamide, and
transferred to nitrocellulose, according to standard protocols(14).
Tissue Samples. Unilateral orchidectomy specimens sus-
pected for the presence of a TGCT, collected at the operation
theater of collaborating hospitals, were divided into two
representative portions, one of which was snap frozen in liquid
nitrogen, the other of which was fixed in 4% buffered Formalin
and embedded in paraffin. Tumors were classified according to
the recommendations of the World Health Organization (15),
as described previously by Oosterhuis et al. (16).
For isolation of total RNA from the tumors, a series of
10-15 thick sections (thickness 4 ,um) was cut from a repre-
sentative frozen sample. The first and last sections were fixed
for 5 min at room temperature in 100% acetone and stained
with hematoxylin and eosin for histological examination. Since
this protocol is unreliable for identification of CIS, this com-
ponent was identified by histological staining for alkaline
phosphatase, as follows. Fixed tissue sections were incubated
for 10-20 min in the dark in 0.2 M Tris-HCl (pH 8.0),
containing naphthol AS-MX phosphate at 0.8 mg/ml, 10%(vol/vol) N,N-dimethylformamide, and fast red TR at 1.1
mg/ml (all three chemicals from Sigma). Sections were coun-
terstained with hematoxylin, washed with tap water, and
subsequently embedded in 50% glycerol and 7% gelatin(Merck).
The remaining tissue sections were used for RNA isolation
with the RNA-STAT-60 kit (Tel-Test, Friendswood, TX)
according to the manufacturer's recommendations. All RNAs
were stored at -80°C in 70% ethanol until use.
Reverse Transcriptase (RT)-PCR of PDGF a-Receptor
Transcripts. For detection of PDGF a-receptor transcripts,
the following PCR oligonucleotide primers were used: exon
12-specific primer (5'-GACCCGATGCAGCTGCCTTA-3';
nucleotides 1864-1883 in ref. 17), intron 12-specific primer(5'-TGCAGAAAGCTGAGGAGGCGTCTGG-3'; nucleo-
tides 152-176 in ref. 13), exon 19-specific primer (5'-
CACGGGCAGAAAGGTACTGCCT-3'; nucleotides 2684-
2705 in ref. 17), and teratocarcinoma cryptic exon-specific
primer (5'-GACTCAGGTTCCTCTGACATCTCG-3'; nucle-
otides 770-793 in ref. 13). Primers 243 and 244 (18) of the
human hypoxanthine phosphoribosyltransferase (HPRT) gene
were used for RNA quality control.
For RT-PCR analysis, cDNA synthesis on 0.5 ,Lg of tumor-
derived RNA was performed as described by Van Gurp et al.(19). After initial denaturation for 4 min at 94°C, subsequently
either 32 or 42 cycles were carried out consisting of 1 min of
denaturation at 94°C, 1 min of annealing at 65°C, and 2 min of
extension at 72°C. The reaction vials were then incubated for
7 min at 72°C and stored at 4°C. If necessary, a booster PCR
was carried out after 32 cycles by transferring one-tenth of the
PCR volume (5 ,Il) to a vial containing fresh enzyme, nucle-
otides, and primers, after which another 20 PCR cycles were
carried out. The same protocol was used for HPRT expression
analysis using 32 cycles, with the exception that annealing was
carried out at 62°C. PCR products (5 atl) were analyzed on
1.5% agarose gels in Tris/borate/EDTA (TBE; Gibco/BRL)
by ethidium bromide staining and UV exposure. When nec-
essary, DNA was transferred to Hybond N+ nylon filters
(Amersham), and hybridized with PDGF a-receptor-specific
32P-labeled oligonucleotides (14).
RESULTS
PDGF a-Receptor Transcripts in Tera-2 Cells. We have
previously shown by Northern blot analysis that undifferenti-
ated Tera-2 EC cells express two PDGF a-receptor transcripts
of 1.5 kb and 5.0 kb, while RA-differentiated cells (Tera-2 RA)
express only a single 6.4-kb transcript. The 1.5-kb transcript has
been shown to initiate within intron 12 of the PDGF a-recep-
tor gene, and it contains exons 13-16, followed by a so-called
teratocarcinoma cryptic exon (TCCE) which contains a func-
tional polyadenylylation signal (13). The size of the 5.0-kb
transcript suggested that it might result from transcription
initiation at the same site within intron 12, but in combination
with normal splicing to downstream exons. To investigate
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FIG. 1. Characterization of PDGF a-receptor transcripts in Tera-2
cells by RT-PCR analysis of products. Lane 1, Tera-2 EC mRNA and
intron 12-specific primer in combination with exon 19-specific primer(expected size of product from 5.0-kb transcript: 850 bp). Lane 2,
Tera-2 EC mRNA and intron 12-specific primer in combination with
TCCE-specific primer (expected size of product from 1.5-kb tran-
script: 641 bp). Lane 3, Tera-2 RA mRNA and exon 12-specific primer
in combination with exon 19-specific primer (expected size of product
from 6.4-kb transcript: 841 bp). Lane 4, Tera-2 RA mRNA and exon
12-specific primer in combination with TCCE-specific primer (expect-
ed size of product from 3.0-kb transcript: 632 bp). Besides direct
staining on gels with ethidium bromide (A), blots were hybridized with
the following 32P-labeled oligonucleotides: (B) Exon 16-specific
primer (5'-GGACATGAAGCAGGCTGATACT-3'; nucleotides
2324-2345 in ref. 17 and 621-642 in ref. 13). (C) Intron 12-specific
primer downstream from primer used for PCR (5'-CCAGACGCCTC-
CTCAGCT-3'; nucleotides 159-176 in ref. 13). (D) Primer specific for
the exon 16-TCCE transition (5'-CCAGCCCAGCCTAACATAGA-
3'; nucleotides 739-758 in ref. 13). Bars on the left represent 861-bp
and 480-bp size markers derived from pKUN digested with Taq I.
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the PDGF a-receptor gene are indeed independent phenom-
ena, we set up an RT-PCR strategy for detection of the
different PDGF a-receptor transcripts, using an exon 12-
specific primer, an intron 12-specific primer, a primer down-
stream of exon 16 (presumably in exon 19), and a TCCE-
specific oligonucleotide (sequences are given in Materials and
Methods).
Fig. 1 shows that by using combinations of the above primers
four different RT-PCR products can be detected in Tera-2
cells, depending on their differentiation state, which all hy-
bridize with an exon 16-specific probe for the PDGF a-recep-
tor. In Tera-2 EC cells PCR products were obtained only when
the intron 12-specific primer was used, in combination with
either the TCCE-specific primer or the exon 19-specific
primer. These two products correspond to the 1.5-kb transcript
and a 5.0-kb transcript with the above characteristics, respec-
tively (see Fig. 2). The present characterization of the 5.0-kb
transcript agrees with previous observations that this transcript
does not hybridize with a TCCE-specific probe on Northern
blots (13). In Tera-2 RA cells PCR products were obtained
only when the exon 12-specific primer was used. In combina-
tion with the exon 19-specific primer, evidence was found for
the full-length 6.4-kb transcript. An additional transcript,
however, so far unknown, was found in combination with a
TCCE-specific primer. The predicted transcript would corre-
spond to exons 1-16 followed by TCCE, with a calculated size
of 3.0 kb (Fig. 2). This hypothesis is confirmed by the obser-
vation that some human glioma cells, which show significant
expression of a 3.0-kb PDGF a-receptor transcript by North-
ern blot analysis, also show hybridization with a TCCE-specific
probe (S.M., M. Nist6r, G. B. Afink, and E.J.J.v.Z., unpub-
lished observation).
Fig. 2 also illustrates the putative protein products encoded
by these four PDGF a-receptor transcripts. Exons 13-16,
which are present in all four transcripts, encode the first
tyrosine kinase domain and part of the interkinase domain of
the PDGF a-receptor (13). The 6.4-kb transcript encodes the
full-length receptor, while the 3.0-kb transcript will encode a
receptor variant lacking the second tyrosine kinase domain,
structurally very similar to that of a dominant-negative recep-
tor mutant described elsewhere (20). The 1.5-kb and 5.0-kb
transcripts potentially encode cytoplasmic truncated forms of
the PDGF a-receptor. Moreover, an alternative open reading
frame in intron 12 and exon 13 potentially encodes a peptide
of 66 amino acids, with no homology to any other protein (13).
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FIG. 2. Survey of human PDGF a-receptor transcripts and putative
protein products. (Left) Organization ofPDGF a-receptor transcripts,
with corresponding size (kb). Black areas indicate regions correspond-
ing to the full-length receptor sequence, gray areas indicate intron 12
sequences, and hatched areas, TCCE sequences. Lines indicate the
location of the PCR primers used for individual detection of these
transcripts. (Right) Putative protein products corresponding to the
respective transcripts. Gray areas are derived from intron 12 and exon
12 sequences (alternative reading frame), and hatched areas are from
TCCE. TM stands for transmembrane region, and TK-1 and TK-2 for
tyrosine kinase domains. Looped structures indicate immunoglobulin-
like domains.
of any of the alternative PDGF a-receptor transcripts de-
scribed here.
Expression of 1.5-kb PDGF a-Receptor Transcript in
TGCTs. In view of our observation that the 1.5-kb PDGF
a-receptor transcript is expressed in undifferentiated but not
in differentiated Tera-2 EC cells, we addressed the question of
whether this transcript is also expressed in TGCTs. When the
above RT-PCR analysis based on an intron 12-specific primer
in combination with a TCCE-specific primer was used, all SE
and NS tested were found to be positive for the 1.5-kb
transcript, as shown if Table 1. All control samples, including
placenta, testis parenchyma of control individuals, and control
semen, were found to be negative. In addition, testis paren-
chyma next to a TGCT was found to be negative when devoid
of both CIS and invasive malignant components. The expres-
sion levels observed were expressed as a function of the
























































































Semen (normal individuals) (n = 3)
Placenta (third trimester) (n = 1)
Testis parenchyma control individuals (n = 3)
Testis parenchyma next to tumort (n = 10)
A total of 57 unilateral orchidectomy specimens suspected for the
presence of a TGCT were given individual code numbers and classified
histologically as described (16). Twenty-nine of these specimens,
containing invasive TGCT, were analyzed for the expression of the
1.5-kb PDGF a-receptor transcript. In the case of NS both pure and
mixed tumors were analyzed as indicated. Testis parenchyma of
control individuals was obtained from patients who had died of reasons
other than a TGCT.
*Quantification of expression levels: + + +, detectable after 32 PCR
cycles; + +, detectable after 42 PCR cycles; +, detectable only after
32 PCR cycles and an additional booster with 20 PCR cycles; +/-,
detection not certain after booster PCR; -, not detectable after
booster PCR.
tTestis parenchyma without the presence of CIS or invasive malignant
component.
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FIG. 3. Histological section of testis parenchyma containing CIS,
stained for alkaline phosphatase. (Upper) Low-power magnification(x55) of testicular parenchyma containing seminiferous tubules with-
out CIS in the central area, surrounded by a large number of tubules
containing CIS. CIS cells are arranged as strings of beads. (Lower)
High-power magnification (x180) of a single seminiferous tubule
containing CIS.
number of PCR cycles required for detection of the transcript
(see legend of Table 1). All negative controls were analyzed by
the booster PCR protocol, as described. Although the present
PCR analysis gives no quantitative information about the level
of expression, it is striking that those NS which contain only EC
cells and no differentiated components show detection at a
lower number of cycles than those containing differentiated
CH, TE, or YS components. This is in line with the observation
that Tera-2 EC cells lose expression of the 1.5-kb transcript
upon differentiation to mature cell types. The observed ex-
pression in the NS therefore most likely reflects the presence
of undifferentiated EC stem cells in these mixed tumors.
Expression of 1.5-kb PDGF a-Receptor Transcript in CIS.
Since CIS is the precursor of both SE and NS, the above
observation prompted us to investigate if CIS cells also express
the 1.5-kb transcript. CIS is generally present in seminiferous
tubules adjacent to all histological types of TGCTs. From a
number of the TGCTs, testis parenchyma was analyzed for the
presence of CIS, as described in Materials and Methods. Fig. 3
shows a section containing CIS, stained for alkaline phos-
phatase. On the basis of the percentage of CIS-containing
seminiferous tubules in the sections, the tissue was classified by
a CIS index (see legend of Fig. 4). The data in Fig. 4 show that
with a booster PCR the 1.5-kb PDGF a-receptor transcript
could be detected in all CIS-positive samples, with a detection
limit below 10% of CIS-positive tubules. Case 24, an atrophic
testis without CIS, showed expression due to the presence of
micro-invasive SE (not shown). Therefore, no false positive
results were obtained. Although the PCR analysis cannot be
considered to give quantitative results, a correlation was
observed between the intensity of the PCR signal and the CIS
index, again indicating that the CIS cells are most likely
responsible for the expression of the 1.5-kb transcript. In
addition, all controls and tissues from unrelated tumors,
including Leydig cell tumor, were found to be negative for this
marker. These data show that the 1.5-kb PDGF a-receptor
transcript can be considered as an absolute marker for CIS
cells of the testis and their derivatives.
DISCUSSION
In the present study we have shown that expression of the
1.5-kb PDGF a-receptor transcript is a highly selective marker
for testicular germ cell tumors and their precursor, CIS.
TGCTs are a significant cause of death for young adults, and
the incidence of this type of tumor is still increasing (1, 2). As
a consequence there is great need for a diagnostic method by
which individuals at risk can be screened for early, preinvasive,
stages of the disease (9). Existing methods rely on histological
detection of CIS cells in testis parenchyma after surgical
biopsy. However, CIS cells have also been detected in semen
samples of tumor patients (21) and are also expected to be
present in cell suspensions obtained by fine needle aspiration
cytology of the testes of these patients (9). The present
observation that CIS cells can be detected with high selectivity
and PCR-based sensitivity opens the possibility of setting up
diagnostic screening for CIS based on detection of the 1.5-kb
PDGF a-receptor transcript in samples obtained by such non-
or minimally invasive techniques.
Markers currently available for TGCTs can be subdivided
into two categories; one is based on the embryonic origin of
these cells, the other on specific initiation and progression
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FIG. 4. Expression of the 1.5-kb PDGF a-receptor transcript in CIS. Testis parenchyma adjacent to TGCTs, but free of an invasive tumor
component, was analyzed histochemically on sections for the fraction of seminiferous tubules containing CIS. This was quantified in a CIS index
as follows: 0 (0% CIS), 1 (<10% CIS), 2 (10-40% CIS), 3 (40-75% CIS), and 4 (75-100% CIS). RNA was analyzed from parallel sections. The
1.5-kb transcript was detected by a booster PCR, with HPRT as RNA quality control. HPRT products are shown after staining of gel with ethidium
bromide; 1.5-kb transcript PCR products, after hybridization of blots with an exon 16-specific probe (see legend of Fig. 1). The following
abbreviations were used for histological characterization (Hist.): S, parenchyma adjacent to SE; N, parenchyma adjacent to NS; C, parenchyma
adjacent to a combined tumor; P, normal testis; A, atrophic parenchyma; L, Leydig cell tumor. mRNA from Tera-2 EC cells was used as a positive
control.
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events during the tumorigenic process. The best-characterized
tumor marker for TGCTs is the consistent overrepresentation
of chromosome 12p sequences (22), while in addition mono-
clonal antibodies have been characterized which specifically
recognize CIS cells in the testis (9). Using a combination of
chromosomal and immunological markers for selecting cells by
flow cytometry, attempts have been made to detect CIS cells
in body fluids, but so far the diagnostic sensitivity of this
method appears to be insufficient. Just as for alkaline phos-
phatase, the 1.5-kb PDGF a-receptor transcript is most likely
already expressed in primordial germ cells. It is anticipated
that expression of the 1.5-kb transcript is lost after the initial
differentiation steps of the primordial germ cells to gonocytes
in early life. If derangement of these primordial germ cells
occurs, so that cellular differentiation is blocked, the derived
CIS cells and TGCTs will still express the 1.5-kb transcript,
until differentiation of NS stem cells to mature cell types takes
place.
In the present study we have found evidence for four
different PDGF a-receptor transcripts. The 6.4- and 3.0-kb
transcripts are transcribed from a promoter upstream of exon
1 of the PDGF a-receptor gene (23), while the 5.0- and 1.5-kb
transcripts appear to be transcribed from a promoter within
intron 12 of the gene (13). Besides the 1.5-kb transcript, the
tumors studied here generally also expressed the 5.0-kb tran-
script, which initiates from the same promoter but undergoes
alternative splicing. Moreover, abundant expression of both
the 6.4- and 3.0-kb transcripts was detected in all tissues,
including the negative control samples presented in Table 1
and Fig. 4 (data not shown). Most likely these transcripts derive
from stromal cells which have been removed with the tumor.
In agreement with previous studies, we also found evidence for
a 1.4-kb PDGF a-receptor transcript, which corresponds to the
1.5-kb transcript lacking exon 14 as a result of alternative
splicing (13). Most likely exon 14-lacking variants exist for all
four PDGF a-receptor transcripts described in this study.
The present data show that the 1.5-kb PDGF a-receptor
transcript can be considered as a highly selective marker for
TGCTs and CIS. Although we have tested only a limited
number of control tissues so far, CIS cells appear to be the
only cells expressing the 1.5-kb transcript in testis paren-
chyma. It may be possible to use the present RT-PCR
analysis to set up a diagnostic assay for testing semen samples
and cell suspensions obtained by aspiration cytology for the
presence of CIS. Furthermore, the transcriptional regulation
of the 1.5-kb transcript might be studied by analysis of the
alternative promoter within intron 12 of the gene. Recent
observations show that this second PDGF a-receptor pro-
moter contains a functional binding site for the Oct family of
transcription factors, while additional experiments indicate
that Tera-2 cells express the Oct-4 gene only in the undif-
ferentiated state (H.J.K., E. Piek, and E.J.J.v.Z., unpub-
lished observation). Many early embryonic cells, including
mouse primordial germ cells (24), express the Oct-4 gene,
which may be a prerequisite for activity of the second PDGF
a-receptor promoter. Interestingly, NS but not SE has been
shown to express the FGF-4 gene, which is also known to be
controlled by Oct-4 (25, 26).
1. M0ller, H. (1993) Eur. Urol. 23, 8-15.
2. Swerdlow, A. J. (1993) Eur. Urol. 23, 35-38.
3. Damjanov, I. (1991) in Recent Results in Cancer Research, eds.
Oosterhuis, J. W., Walt, H. & Damjanov, I. (Springer, Berlin),
Vol. 123, pp. 1-19.
4. Andrews, P. W. (1988) Biochim. Biophys. Acta 948, 17-36.
5. Skakkebaek, N. E., Berthelsen, J. G., Giwercman, A. & Miller, J.
(1987) Int. J. Androl. 10, 19-28.
6. J0rgensen, N., Rajpert-de Meyrs, E., Graem, N., Muller, J.,
Giwercman, A. & Skakkebaek, N. E. (1995) Lab. Invest. 72,
223-231.
7. Giwercman, A. & Skakkebaek, N. E. (1993) Eur. Urol. 23, 19-21.
8. Giwercman, A., Vor der Maase, H., Berthelsen, J. G., R0rth, M.,
Bertelsen, A. & Skakkebask, N. E. (1991) J. Clin. Endocr. Metab.
73, 596-603.
9. Giwercman, A. (1992) Scand. J. Urol. Nephrol. 148, Suppl., 1-47.
10. Raines, E. W., Bowen-Pope, D. F. & Ross, R. (1991) in Peptide
Growth Factors and Their Receptors, eds. Sporn, M. B. & Roberts,
A. B. (Springer, New York), Vol. 1, pp. 173-262.
11. Rosnet, O. & Birnbaum, D. (1993) Crit. Rev. Oncogen. 4,
595-613.
12. Palmieri, S. L., Stiles, C. D. & Mercola, M. (1993) in Biology of
Platelet-Derived Growth Factor, eds. Westermark, B. & Sorg. C.
(Karger, Basel), Vol. 5, pp. 115-128.
13. Mosselman, S., Claesson-Welsh, L., Kamphuis, J. S. & Van
Zoelen, E. J. J. (1994) Cancer Res. 54, 220-225.
14. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular
Cloning: A Laboratory Manual (Cold Spring Harbor Lab. Press,
Plainview, NY), 2nd Ed.
15. Mostofi, F. K., Sesterhenn, I. A. & Davis, C. J. J. (1987) Sem.
Diagn. Pathol. 4, 320-341.
16. Oosterhuis, J. W., Castedo, S. M. M. J., de Jong, B., Cornelisse,
C. J., Dam, A., Sleijfer, D. T. & Schraffordt Koops, H. (1989)
Lab. Invest. 60, 14-20.
17. Claesson-Welsh, L., Eriksson, A., Westermark, B. & Heldin,
C. H. (1989) Proc. Natl. Acad. Sci. USA 86, 4917-4921.
18. Gibbs, R. A., Nguygen, P. N., McBride, L. J., Koepf, S. M. &
Caskey, C. T. (1989) Proc. Natl. Acad. Sci. USA 86, 1919-1923.
19. Van Gurp, R. J. L. M., Oosterhuis, J. W., Kalscheuer, V., Mari-
man, E. C. M. & Looijenga, L. H. J. (1994) J. Natl. Cancer Inst.
86, 1070-1075.
20. Ueno, H., Escobedo, J. A. & Williams, L. T. (1993)J. Biol. Chem.
268, 22814-22819.
21. Giwercman, A., Hopman, A. H. N., Ramaekers, F. C. S. & Skak-
kebaek, N. E. (1990) Am. J. Pathol. 146, 497-502.
22. De Jong, B., Oosterhuis, J. W., Castedo, S. M. M. J., Vos, A. &
Te Meerman, G. (1990) Cancer Genet. Cytogenet. 48, 143-167.
23. Afink, G. B., Nistdr, M., Stassen, B. H. G. J., Joosten, P. H. L. J.,
Rademakers, P. J. H., Bongcam-Rudloff, E., van Zoelen, E. J. J.
& Mosselman, S. (1995) Oncogene 10, 1667-1672.
24. Scholer, H. R., Dressier, G. R., Balling, R., Rohdeworld, H. &
Gruss, P. (1990) EMBO J. 9, 2185-2195.
25. Strohmeyer, T., Peter, S., Hartmann, M., Munemitsu, S., Ack-
ermann, R., Ullrich, A. & Slamon, D. J. (1991) Cancer Res. 51,
1811-1816.
26. Ma, Y. G., Rosfjord, E., Huebert, C., Wilder, P., Tiesman, J.,
Kelly, D. & Rizzino, A. (1992) Dev. Biol. 154, 45-54.
Proc. Natl. Acad. Sci. USA 93 (1996)
